Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Indanyloxydihydrobenzofuranylacetic acids
8642585 Indanyloxydihydrobenzofuranylacetic acids
Patent Drawings:

Inventor: Eckhardt, et al.
Date Issued: February 4, 2014
Application:
Filed:
Inventors:
Assignee:
Primary Examiner: Shterengarts; Samantha
Assistant Examiner:
Attorney Or Agent: Morris; Michael P.Witkowski; Timothy X.
U.S. Class: 514/211.01; 514/233.5; 514/252.01; 514/255.05; 514/256; 514/337; 514/364; 514/365; 514/374; 514/382; 514/383; 514/385; 514/406; 514/422; 514/432; 514/469; 540/544; 544/124; 544/153; 544/238; 544/242; 544/336; 546/284.1; 548/131; 548/202; 548/235; 548/262.2; 548/315.4; 548/364.4; 548/525; 549/13; 549/462
Field Of Search: ;514/211.01; ;514/233.5; ;514/252.01; ;514/255.05; ;514/256; ;514/337; ;514/364; ;514/365; ;514/374; ;514/382; ;514/383; ;514/385; ;514/406; ;514/422; ;514/432; ;514/469; ;540/544; ;544/124; ;544/153; ;544/238; ;544/242; ;544/336; ;546/284.1; ;548/131; ;548/202; ;548/235; ;548/262.2; ;548/315.4; ;548/364.4; ;548/525; ;549/13; ;549/462
International Class: A61K 31/553; C07D 267/10; C07D 413/02; A61K 31/382; C07D 409/02; A61K 31/4025; A61K 31/4196; C07D 249/08; A61K 31/41; A61K 31/506; A61K 31/501; C07D 277/20; A61K 31/427; C07D 271/06; A61K 31/4245; A61K 31/443; C07D 405/02; A61K 31/4155; C07D 307/77; A61K 31/343; C07D 257/02; C07D 403/02; A61K 31/5377; C07D 413/14; A61K 31/497; C07D 231/10; A61K 31/422; C07D 263/30; A61K 31/4178; C07D 233/54
U.S Patent Documents:
Foreign Patent Documents: 1559422; 1630152; 2006271; 2289868; 2008001931; 2009157418; 201045258; 2010143733; 2012072691
Other References: Itoh, et al., Free fatty acids regulate insulin secretion from pancreatic b cells through GPR40, Letters to Nature, 2003, vol. 422, p.173-176. cited by applicant.
Briscoe, et al., "The Orphan G Protein-coupled Receptor GPR40 is activated by Medium and Long Chain Fatty Acids", Journal of Biological Chemistry, vol. 278, No. 13, 2003, p. 11303-11311. cited by applicant.
Kotarsky, et al., "A human cell surface receptor activated by free fatty acids and thiazolidine drugs'", Biochemical and Biophysical Research Communications, vol. 301, No. 2, 2003, p. 406-410. cited by applicant.
Song et al., "Synthesis and Biological Evaluation of 3-Aryl-3-(4-phenoxy)-propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists", Journal of Medicinal Chemistry, vol. 50, 2007, p. 2807-2817. cited by applicant.
Tan, et al., "Selective Small-Molecule Agonists of G Protein-coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice", Diabetes, vol. 57, 2008, p. 2211. cited by applicant.
Mikami, Satoshi et al. "Discovery of Phenylpropanoic Acid Derivatives Containing Polar Functionalities as Potent and Orally Bioavailable G Protein-Coupled Receptor 40 Agonists for the Treatment of Type 2 Diabetes" Journal of Medicinal Chemistry(2012) 55, 3756-3776. cited by applicant.
Negoro, Nobuyuki et al. "Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40/ Free Fatty Acid Receptor 1 Agonists" Journal of Medicinal Chemistry, (2012) 55, pgs. 1538-1552.cited by applicant.
International Search Report for PCT/EP2013/056312 mailed on May 27, 2013. cited by applicant.
Mikami, et al., "Discovery of Phenylpropanoic Acid Derivatives Containing Polar Functionalities as Potent and Orally Bioavailable G Protein-Coupled Receptor 40 Agonists for the Treatment of Type 2 Diabetes", Journal of Medicinal Chemistry, 2012, V.55, No. 8, p. 3756-3776. cited by applicant.
International Search Report and written opinion for PCT/EP 2013/058840 mailed Aug. 22, 2013. cited by applicant.









Abstract: The present invention relates to compounds of general formula I, ##STR00001## wherein the groups R.sup.1, R.sup.2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Claim: The invention claimed is:

1. A compound of formula (I) ##STR00453## wherein: R.sup.1 is selected from the group consisting of a phenyl ring, a tetrazolyl ring, and a 5- or 6-memberedheteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from .dbd.N--, --NH--, --O--, and --S--, wherein optionally a second ring is annulated to the phenyl or heteroaromatic ring, wherein the second ring is 5- or 6-membered,unsaturated or aromatic and optionally contains 1, 2, or 3 heteroatoms independently selected from .dbd.N--, --NH--, --O--, and --S--, with the proviso that only up to two of the heteroatoms are O and S and no O--O, S--S, or S--O bond is formed, and inthe second ring independently 1 or 2 CH.sub.2 groups are optionally replaced by --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and the phenyl ring, tetrazolyl ring, heteroaromatic ring, annulated phenyl ring, and annulated heteroaromatic ring aresubstituted with one group R.sup.3; each of the phenyl ring, tetrazolyl ring, heteroaromatic ring, annulated phenyl ring, and annulated heteroaromatic ring is optionally additionally substituted with 1 to 4 groups independently selected from R.sup.4; and in the heteroaromatic ring and/or the second ring the H-atom in one or more NH groups, if present, is replaced by R.sup.N or R.sup.3; R.sup.2 is F, Cl, Br, I, C.sub.1-4-alkyl, C.sub.3-6-cycloalkyl, NC--, H.sub.2N--C(.dbd.O)--,C.sub.1-4-alkyl-NR.sup.N--C(.dbd.O)--, HO--C(.dbd.O)--, C.sub.1-4-alkyl-O--C(.dbd.O)--, C.sub.1-4-alkyloxy, or C.sub.1-4-alkyl-S(.dbd.O).sub.2--, wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substitutedwith one or more F atoms, and wherein multiple R.sup.2 are identical or different, if m is 2 or 3; R.sup.3 is selected from the group consisting of C.sub.1-6-alkyl, C.sub.2-6-alkenyl, C.sub.2-6-alkinyl, C.sub.3-6-cycloalkyl-, C.sub.1-4-alkyl-NH--,(C.sub.1-4-alkyl).sub.2N--, C.sub.1-6-alkyl-O--, C.sub.3-6-cycloalkyl-O--, C.sub.1-4-alkyl-S--, C.sub.1-4-alkyl-S(.dbd.O)--, and C.sub.1-4-alkyl-S(.dbd.O).sub.2, wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within thegroups mentioned is substituted with 1 to 3 groups independently selected from R.sup.5 and optionally substituted with 1 or more F atoms; or selected from C.sub.1-4-alkyl-C(.dbd.O)--, heterocyclyl-C(.dbd.O)--, HNR.sup.N--C(.dbd.O)--,C.sub.1-4-alkyl-NR.sup.N--C(.dbd.O)--, C.sub.3-6-cycloalkyl-NR.sup.N--C(.dbd.O)--, heterocyclyl-NR.sup.N--C(.dbd.O)--, phenyl-NR.sup.N--C(.dbd.O)--, heteroaryl-NR.sup.N--C(.dbd.O)--, HO.sub.2C--, C.sub.1-4-alkyl-O--C(.dbd.O)--,C.sub.3-6-cycloalkyl-O--C(.dbd.O)--, heterocyclyl-O--C(.dbd.O)--, --NHR.sup.N, C.sub.1-4-alkyl-C(.dbd.O)NR.sup.N--, C.sub.3-6-cycloalkyl-C(.dbd.O)NR.sup.N--, heterocyclyl-C(.dbd.O)NR.sup.N--, phenyl-C(.dbd.O)NR.sup.N--, heteroaryl-C(.dbd.O)NR.sup.N--,C.sub.1-4-alkyl-S(.dbd.O).sub.2NR.sup.N--, C.sub.3-6-cycloalkyl-S(.dbd.O).sub.2NR.sup.N--, heterocyclyl-S(.dbd.O).sub.2NR.sup.N--, phenyl-S(.dbd.O).sub.2NR.sup.N--, heteroaryl-S(.dbd.O).sub.2NR.sup.N--, heterocyclyl-O--, phenyl-O--, heteroaryl-O--,C.sub.3-6-cycloalkyl-S--, heterocyclyl-S--, phenyl-S--, heteroaryl-S--, C.sub.3-6-cycloalkyl-S(.dbd.O)--, heterocyclyl-S(.dbd.O)--, phenyl-S(.dbd.O)--, heteroaryl-S(.dbd.O)--, C.sub.3-6-cycloalkyl-S(.dbd.O).sub.2--, heterocyclyl-S(.dbd.O).sub.2--,phenyl-S(.dbd.O).sub.2--, heteroaryl-S(.dbd.O).sub.2--, HNR.sup.N--S(.dbd.O).sub.2--, C.sub.1-4-alkyl-NR.sup.N--S(.dbd.O).sub.2--, heterocyclyl, phenyl, and heteroaryl, wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groupsmentioned is optionally substituted with 1 to 3 groups independently selected from R.sup.5 and optionally substituted with 1 or more F atoms; and wherein each phenyl and heteroaryl group is optionally substituted with 1 to 5 substituents independentlyselected from R.sup.6; heterocyclyl is selected from a cyclobutyl group wherein 1 CH.sub.2 group is replaced by --NH-- or --O--, a saturated or partially unsaturated C.sub.5-7-cycloalkyl group wherein 1 CH.sub.2 group is replaced by --C(.dbd.O)--,--NH--, --O--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; a saturated or partially unsaturated C.sub.5-7-cycloalkyl group wherein a first CH.sub.2 group is replaced by --NH-- or --O--, a second CH.sub.2 group is replacedby --NH--, --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; and a saturated or partially unsaturated C.sub.5-7-cycloalkyl group wherein 2 CH.sub.2 groups are replaced by --NH--, or a first CH.sub.2 group isreplaced by --NH--, a second CH.sub.2 group is replaced by --O--, and a third CH.sub.2 group by --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2-- and/or 1 CH group is replaced by N; wherein heteroaryl is selected from a tetrazolyl ring, and a 5- or6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from .dbd.N--, --NH--, --O--, and --S--, wherein in heteroaromatic groups containing a --HC.dbd.N-- unit this group is optionally replaced by --NH--C(.dbd.O)--; wherein in heteroaryl and heterocyclyl rings with one or more NH groups each of them is replaced by NR.sup.N or NR.sup.5; with the proviso that R.sup.3 in total cannot be C.sub.1-4-alkyl-, C.sub.1-4-alkyl-O--C.sub.1-4-alkyl, HO--C.sub.1-4-alkyl,C.sub.3-4-alkenyl, C.sub.1-4-alkyl-NH--, (C.sub.1-4-alkyl).sub.2N--, C.sub.1-4-alkyl-S--, C.sub.1-4-alkyl-S(.dbd.O)--, and C.sub.1-4-alkyl-S(.dbd.O).sub.2; R.sup.4 is F, Cl, Br, I, CN, --OH, C.sub.1-4-alkyl, C.sub.3-6-cycloalkyl-, HO--C.sub.1-4-alkyl,C.sub.1-4-alkyl-O--C.sub.1-4-alkyl, --NR.sup.NH, C.sub.1-4-alkyl-NR.sup.N--, C.sub.1-4-alkyl-O--, C.sub.3-6-cycloalkyl-O--, C.sub.1-4-alkyl-S--, C.sub.1-4-alkyl-S(.dbd.O)--, or C.sub.1-4-alkyl-S(.dbd.O).sub.2--, wherein any alkyl and cycloalkyl group orsub-group within the groups mentioned is optionally substituted with 1 or more F atoms; R.sup.5 is selected from the group consisting of Cl, Br, I, C.sub.1-4-alkyl-, CN, C.sub.3-6-cycloalkyl-, heterocyclyl-C(.dbd.O)--, H.sub.2N--C(.dbd.O)--,C.sub.1-4-alkyl-NR.sup.N--C(.dbd.O)--, C.sub.3-6-cycloalkyl-NR.sup.N--C(.dbd.O)--, heterocyclyl-NR.sup.N--C(.dbd.O)--, phenyl-NR.sup.N--C(.dbd.O)--, heteroaryl-NR.sup.N--C(.dbd.O)--, HO--C(.dbd.O)--, C.sub.1-4-alkyl-O--C(.dbd.O)--, --NHR.sup.N,NR.sup.NC.sub.1-4-alkyl-C(.dbd.O)NR.sup.N--, C.sub.3-6-cycloalkyl-C(.dbd.O)NR.sup.N--, heterocyclyl-C(.dbd.O)NR.sup.N--, phenyl-C(.dbd.O)NR.sup.N--, heteroaryl-C(.dbd.O)NR.sup.N--, C.sub.1-4-alkyl-S(.dbd.O).sub.2NR.sup.N--,C.sub.3-6-cycloalkyl-S(.dbd.O).sub.2NR.sup.N--, heterocyclyl-S(.dbd.O).sub.2NR.sup.N--, phenyl-S(.dbd.O).sub.2NR.sup.N--, heteroaryl-S(.dbd.O).sub.2NR.sup.N--, --OH, C.sub.1-4-alkyl-O--C.sub.1-4-alkyl-O--, C.sub.3-6-cycloalkyl-O--, heterocyclyl-O--,phenyl-O--, heteroaryl-O--, C.sub.3-6-cycloalkyl-S--, heterocyclyl-S--, phenyl-S--, heteroaryl-S--, C.sub.1-4-alkyl-S(.dbd.O)--, C.sub.3-6-cycloalkyl-S(.dbd.O)--, heterocyclyl-S(.dbd.O)--, phenyl-S(.dbd.O)--, heteroaryl-S(.dbd.O)--,C.sub.1-4-alkyl-S(.dbd.O).sub.2, C.sub.3-6-cycloalkyl-S(.dbd.O).sub.2--, heterocyclyl-S(.dbd.O).sub.2--, phenyl-S(.dbd.O).sub.2--, heteroaryl-S(.dbd.O).sub.2--, H.sub.2N--S(.dbd.O).sub.2--, C.sub.1-4-alkyl-NR.sup.N--S(.dbd.O).sub.2--, heterocyclyl,phenyl, and heteroaryl, wherein any alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms and optionally substituted with 1 or 2 groups independently selected from H.sub.3C--,HO--, H.sub.3C--O--, and --CN; wherein heterocyclyl is selected from a cyclobutyl group wherein 1 CH.sub.2 group is replaced by --NR.sup.N-- or --O--, a saturated or partially unsaturated C.sub.5-7-cycloalkyl group wherein 1 CH.sub.2 group is replacedby --C(.dbd.O)--, --NR.sup.N--, --O--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; a saturated or partially unsaturated C.sub.5-7-cycloalkyl group wherein a first CH.sub.2 group is replaced by --NR.sup.N--, or --O--, asecond CH.sub.2 group is replaced by --NR.sup.N--, --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2-- and/or 1 CH group is replaced by N; and a saturated or partially unsaturated C.sub.5-7-cycloalkyl group wherein 2 CH.sub.2 groups are replaced by--NR.sup.N--, or a first CH.sub.2 group is replaced by --NR.sup.N--, a second CH.sub.2 group is replaced by --O--, and a third CH.sub.2 group is replaced by --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; andwherein heteroaryl is selected from a tetrazolyl ring, and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently from .dbd.N--, --NH--, --O--, and --S--, wherein in heteroaromatic groups containing a --HC.dbd.N-- unitthis group is optionally replaced by --NR.sup.N--C(.dbd.O)--, and wherein in heteroaromatic rings with one or more NH groups each of them is replaced by NR.sup.N, and each heteroaryl group is optionally substituted with 1 to 3 substituents independentlyselected from F, Cl, --CH.sub.3, --CN, and --O--CH.sub.3; R.sup.6 is F, Cl, Br, I, CN, C.sub.1-4-alkyl, C.sub.3-6-cycloalkyl-, HO--C.sub.1-4-alkyl-, C.sub.1-4-alkyl-O--C.sub.1-4-alkyl-, R.sup.NHN--, C.sub.1-4-alkyl-O--, --S(.dbd.O)--C.sub.1-4-alkyl, orS(.dbd.O).sub.2--C.sub.1-4-alkyl, wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with one or more F atoms; R.sup.N is independently selected from the group consisting of H, C.sub.1-4-alkyl,C.sub.1-4-alkyl-C(.dbd.O)--, C.sub.1-4-alkyl-NH--C(.dbd.O)--, C.sub.1-4-alkyl-N(C.sub.1-4-alkyl)-C(.dbd.O)--, C.sub.1-4-alkyl-O--C(.dbd.O)--, and C.sub.1-4-alkyl-S(.dbd.O).sub.2--; and m is 0, 1, 2, or 3; wherein in any definition mentionedhereinbefore and if not specified otherwise, any alkyl group or sub-group are straight-chained or branched, or a salt thereof.

2. The compound according to claim 1, wherein: R.sup.1 is selected from the group consisting of a phenyl ring, a tetrazolyl ring, a 5-membered heteroaromatic ring which contains 2 or 3 heteroatoms independently selected from .dbd.N--, --NH--,--O--, and --S-- with the proviso that not more than one heteroatom is --O-- or --S--, and a 6-membered heteroaromatic ring which contains 1 or 2=N-- atoms; wherein optionally a second ring is annulated to the phenyl ring and 5- and 6-memberedheteroaromatic rings, wherein the second ring is 5- or 6-membered, unsaturated or aromatic and optionally contains 1 or 2 heteroatoms independently selected from .dbd.N--, --NH--, --O--,and --S-- with the proviso that no O--O, S--S, S--O bond is formed,and in the second ring independently 1 or 2 --CH.sub.2-- groups are optionally replaced by --C(.dbd.O)-- or --S(.dbd.O).sub.2--, in the heteroaromatic ring and/or the second ring the H-atom in one or more NH groups, if present, is replaced by R.sup.N orR.sup.3, and each of the phenyl ring, tetrazolyl ring, heteroaromatic rings, annulated phenyl ring, and annulated heteroaromatic rings is substituted with one group R.sup.3 and optionally additionally substituted with 1 or 2 substituents independentlyselected from R.sup.4; R.sup.2 is F, Cl, Br, H.sub.3C--, H.sub.2FC--, F.sub.3C--, cyclopropyl, NC--, F.sub.2HC--O--, F.sub.3C--O--, or H.sub.3C--S(.dbd.O).sub.2--, R.sup.3 is selected from the group consisting of C.sub.1-4-alkyl, C.sub.3-6-cycloalkyl-,C.sub.1-4-alkyl-O--, C.sub.3-6-cycloalkyl-O--, C.sub.1-4-alkyl-S(.dbd.O)--, and C.sub.1-4-alkyl-S(.dbd.O).sub.2--, wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is substituted with 1 to 3groups independently selected from R.sup.5 and optionally substituted with 1 or more F atoms; or from C.sub.1-4-alkyl-C(.dbd.O)--, heterocyclyl-C(.dbd.O)--, HNR.sup.N--C(.dbd.O)--, C.sub.1-4-alkyl-NR.sup.N--C(.dbd.O)--,C.sub.3-6-cycloalkyl-NR.sup.N--C(.dbd.O)--, heterocyclyl-NR.sup.N--C(.dbd.O)--, phenyl-NR.sup.N--C(.dbd.O)--, heteroaryl-NR.sup.N--C(.dbd.O)--, C(.dbd.O)NR.sup.NC.sub.3-6-cycloalkyl-C(.dbd.O)NR.sup.N--, heterocyclyl-C(.dbd.O)NR.sup.N--,phenyl-C(.dbd.O)NR.sup.N--, heteroaryl-C(.dbd.O)NR.sup.N--, C.sub.1-4-alkyl-S(.dbd.O).sub.2NR.sup.N--, C.sub.3-6-cycloalkyl-S(.dbd.O).sub.2NR.sup.N--, heterocyclyl-S(.dbd.O).sub.2NR.sup.N--, phenyl-S(.dbd.O).sub.2NR.sup.N--,heteroaryl-S(.dbd.O).sub.2NR.sup.N--, heterocyclyl-O--, phenyl-O--, heteroaryl-O--, C.sub.3-6-cycloalkyl-S(.dbd.O)--, heterocyclyl-S(.dbd.O)--, phenyl-S(.dbd.O)--, heteroaryl-S(.dbd.O)--, C.sub.3-6-cycloalkyl-S(.dbd.O).sub.2--,heterocyclyl-S(.dbd.O).sub.2--, phenyl-S(.dbd.O).sub.2--, heteroaryl-S(.dbd.O).sub.2--, HNR.sup.N--S(.dbd.O).sub.2--, C.sub.1-4-alkyl-NR.sup.N--S(.dbd.O).sub.2--, heterocyclyl, phenyl, and heteroaryl, wherein each alkyl, cycloalkyl, and heterocyclylgroup or sub-group within the groups mentioned is optionally substituted with 1 to 3 groups independently selected from R.sup.5 and optionally substituted with 1 or more F atoms; and wherein each phenyl and heteroaryl group is optionally substitutedwith 1 to 3 substituents independently selected from R.sup.6; wherein heterocyclyl is selected from a cyclobutyl group wherein 1 CH.sub.2 group is replaced by --NH-- or --O--, a saturated or mono-unsaturated C.sub.5-6-cycloalkyl group wherein 1 CH.sub.2group is replaced by --C(.dbd.O)--, --NH--, --O--, --S(.dbd.O)--, or --S(.dbd.O).sub.2-- and/or 1 CH group is replaced by N; a saturated or mono-unsaturated C.sub.5-6-cycloalkyl group wherein a first CH.sub.2 group is replaced by --NH-- or --O--, asecond CH.sub.2 group is replaced by --NH--, --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; and a saturated or mono-unsaturated C.sub.5-6-cycloalkyl group wherein 2 CH.sub.2 groups are replaced by --NH--, or afirst CH.sub.2 group is replaced by --NH--, a second CH.sub.2 group is replaced by --O--, and a third CH.sub.2 group is replaced by --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; wherein heteroaryl is selectedfrom a tetrazolyl ring, a pyridin-2-onyl ring, a 5-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from .dbd.N--, --NH--, O, and S, and a 6-membered heteroaromatic ring which contains 1 or 2=N-- atom, and whereinin heteroaryl and heterocyclyl rings with one or more NH groups each of them is replaced by NR.sup.N or NR.sup.5, with the proviso that R.sup.3 in total cannot be C.sub.1-4-alkyl-, C.sub.1-4-alkyl-O--C.sub.1-4-alkyl, HO--C.sub.1-4-alkyl,C.sub.1-4-alkyl-O--, C.sub.1-4-alkyl-S(.dbd.O)--, and C.sub.1-4-alkyl-S(.dbd.O).sub.2, R.sup.4 is F, Cl, Br, CN, C.sub.1-3-alkyl, C.sub.3-4-cycloalkyl-, HO--C.sub.1-3-alkyl, C.sub.1-3-alkyl-O--C.sub.1-3-alkyl, --NR.sup.NH, C.sub.1-4-alkyl-O--,C.sub.3-5-cycloalkyl-O--, H.sub.3C--S(.dbd.O)--, or H.sub.3C--S(.dbd.O).sub.2--, wherein any alkyl and cycloalkyl group is optionally substituted with 1 or more F atoms, R.sup.5 is selected from the group consisting of Cl, C.sub.1-4-alkyl-, --CN,C.sub.3-6-cycloalkyl-, heterocyclyl-C(.dbd.O)--, H.sub.2N--C(.dbd.O)--, C.sub.1-4-alkyl-NR.sup.N--C(.dbd.O)--, C.sub.3-6-cycloalkyl-NR.sup.N--C(.dbd.O)--, heterocyclyl-NR.sup.N--C(.dbd.O)--, heteroaryl-NR.sup.N--C(.dbd.O)--, --NH.sub.2,C.sub.1-4-alkyl-NR.sup.N--, C.sub.1-4-alkyl-C(.dbd.O)NR.sup.N--, C.sub.3-6-cycloalkyl-C(.dbd.O)NR.sup.N--, heterocyclyl-C(.dbd.O)NR.sup.N--, heteroaryl-C(.dbd.O)NR.sup.N--, C.sub.1-4-alkyl-S(.dbd.O).sub.2NR.sup.N--, --OH, C.sub.1-4-alkyl-O--,C.sub.1-4-alkyl-O--C.sub.1-4-alkyl-O--, C.sub.3-6-cycloalkyl-O--, heterocyclyl-O--, phenyl-O--, heteroaryl-O--, C.sub.1-4-alkyl-S(.dbd.O)--, C.sub.3-6-cycloalkyl-S(.dbd.O)--, C.sub.1-4-alkyl-S(.dbd.O).sub.2--, C.sub.3-6-cycloalkyl-S(.dbd.O).sub.2--,heterocyclyl, and heteroaryl, wherein any alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms and optionally substituted with 1 or 2 groups independently selected fromH.sub.3C--, HO--, H.sub.3C--O--, and --CN, wherein heterocyclyl is selected from a cyclobutyl group wherein 1 CH.sub.2 group is replaced by --NR.sup.N-- or --O--; a saturated or partially unsaturated C.sub.5-6-cycloalkyl group wherein 1 CH.sub.2 groupis replaced by --C(.dbd.O)--, --NR.sup.N--, --O--, --S(.dbd.O)--, or --S(.dbd.O).sub.2-- and/or 1 CH group is replaced by N; a saturated or partially unsaturated C.sub.5-6-cycloalkyl group wherein a first CH.sub.2 group is replaced by --NR.sup.N-- or--O--, a second CH.sub.2 group is replaced by --NR.sup.N--, --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2-- and/or 1 CH group is replaced by N; and a saturated or partially unsaturated C.sub.5-6-cycloalkyl group wherein 2 CH.sub.2 group arereplaced by --NR.sup.N--, or a first CH.sub.2 group is replaced by --NR.sup.N--, a second CH.sub.2 group is replaced by --O--, and a third CH.sub.2 group is replaced by --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replacedby N; and wherein heteroaryl is selected from a tetrazolyl ring, a pyridin-2-onyl ring, a 5-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from .dbd.N--, --NH--, --O--, and --S--, and a 6-memberedheteroaromatic ring which contains 1 or 2=N-- atoms, and wherein in heteroaromatic rings with one or more NH groups each of them is replaced by NR.sup.N, and each heteroaryl group is optionally substituted with 1 to 3 substituents independently selectedfrom F, Cl, --CH.sub.3, --CN, and --O--CH.sub.3, R.sup.6 is F, Cl, --CN, C.sub.1-3-alkyl, cyclopropyl, HO--C.sub.1-3-alkyl-, H.sub.3C--O--C.sub.1-3-alkyl-, H.sub.3C--O--, --S(.dbd.O)CH.sub.3, and or --S(.dbd.O).sub.2--CH.sub.3, wherein any alkyl andcycloalkyl group or sub-group within the groups mentioned is optionally substituted with one or more F atoms; R.sup.N is H, C.sub.1-3-alkyl, H.sub.3C--C(.dbd.O)--, or C.sub.1-3-alkyl-S(.dbd.O).sub.2--, m is 0, 1, or 2, or a salt thereof.

3. The compound according to claim 2, wherein: R.sup.1 is a consisting of a phenyl ring, a tetrazolyl ring, a 5-membered heteroaromatic ring which contains 2 or 3 heteroatoms independently selected from .dbd.N--, --NH--, --O--, and --S--, or a6-membered heteroaromatic ring which contains 1 or 2=N-- atoms; wherein in the 5-membered heteroaromatic ring the H-atom in one or more NH groups are replaced with R.sup.N or R.sup.3, and wherein each of the phenyl ring, tetrazolyl ring, andheteroaromatic rings is substituted with one group R.sup.3 and optionally additionally substituted with 1 or 2 substituents independently selected from R.sup.4; and m is 1 or 2, or a salt thereof.

4. The compound according to claim 2, wherein: R.sup.1 is selected from the group consisting of a phenyl ring, a 5-membered heteroaromatic ring which contains 2 or 3 heteroatoms independently selected from .dbd.N--, --NH--, --O-- and --S--, anda 6-membered heteroaromatic ring which contains 1 or 2=N-- atoms, wherein a second 5- or 6-membered, unsaturated or aromatic ring is annulated to the phenyl ring and 5- and 6-membered heteroaromatic rings, which optionally contains 1 or 2 heteroatomsindependently selected from .dbd.N--, --NH--, --O--, and --S--, with the proviso that no O--O, S--S, or S--O bond is formed, and in the second ring 1 or 2 --CH.sub.2-- groups are optionally replaced by --C(.dbd.O)-- or --S(.dbd.O).sub.2--, in theheteroaromatic rings and the second rings the H-atom in one or more NH groups, if present, is replaced by R.sup.N or R.sup.3, and each annulated phenyl ring and annulated heteroaromatic ring is substituted with one group R.sup.3 and optionallyadditionally substituted with 1 or 2 substituents independently selected from R.sup.4; and m is 1 or 2, or a salt thereof.

5. The compound according to claim 1, wherein: R.sup.1 is ##STR00454## wherein each group is substituted with one group R.sup.3 and optionally additionally substituted with 1 or 2 groups independently selected from R.sup.4; R.sup.2 is F, Cl,Br, H.sub.2FC--, F.sub.3C--, NC--, or F.sub.3C--O--; R.sup.3 is selected from the group consisting of C.sub.1-4-alkyl, C.sub.3-6-cycloalkyl-, C.sub.1-4-alkyl-O--, and C.sub.3-6-cycloalkyl-O--, wherein each alkyl and cycloalkyl group and each alkyl andcycloalkyl sub-group within the groups mentioned is substituted with 1 to 3 groups independently selected from R.sup.5 and optionally substituted with 1 or more F atoms; or from H.sub.3C--C(.dbd.O)--, heterocyclyl-C(.dbd.O)--, H.sub.2N--C(.dbd.O)--,C.sub.1-3-alkyl-NR.sup.N--C(.dbd.O)--, C.sub.1-4-alkyl-C(.dbd.O)NR.sup.N--, C.sub.3-6-cycloalkyl-C(.dbd.O)NR.sup.N--, heterocyclyl-C(.dbd.O)NR.sup.N--, C.sub.1-4-alkyl-S(.dbd.O).sub.2NR.sup.N--, heterocyclyl-O--, phenyl-O--, heteroaryl-O--,heterocyclyl-S(.dbd.O).sub.2--, H.sub.2N--S(.dbd.O).sub.2--, heterocyclyl, phenyl, and heteroaryl, wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or 2 groups independentlyselected from R.sup.5 and optionally substituted with 1 or more F atoms; each phenyl and heteroaryl group is optionally substituted with 1 to 3 substituents independently selected from R.sup.6; wherein heterocyclyl is selected from a cyclobutyl groupwherein 1 CH.sub.2 group is replaced by --NH-- or --O--; a saturated or mono-unsaturated C.sub.5-6-cycloalkyl group wherein 1 CH.sub.2 group is replaced by --C(.dbd.O)--, --NH--, --O-- or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; asaturated or mono-unsaturated C.sub.5-6-cycloalkyl group wherein a first CH.sub.2 group is replaced by --NH-- or --O--, a second CH.sub.2 group is replaced by --C(.dbd.O)-- or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; and whereinheteroaryl is selected from a pyridin-2-onyl ring, a 5-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from .dbd.N--, --NH--, O, and S, and a 6-membered heteroaromatic ring which contains 1 or 2=N-- atoms, andwherein in heteroaryl and heterocyclyl rings with one or more NH groups each of them is replaced by NR.sup.N or NR.sup.5; with the proviso that R.sup.3 in total cannot be C.sub.1-4-alkyl-, C.sub.1-4-alkyl-O--C.sub.1-4-alkyl, HO--C.sub.1-4-alkyl, andC.sub.1-4-alkyl-O--; R.sup.4 is F, Cl, CN, --CH.sub.3, --CF.sub.3, isopropyl, cyclopropyl, H.sub.3C--O--CH.sub.2--, H.sub.3C--O--, or F.sub.3C--O--; R.sup.5 is selected from the group consisting of C.sub.1-4-alkyl-, --CN, C.sub.3-6-cycloalkyl-,heterocyclyl-C(.dbd.O)--, H.sub.2N--C(.dbd.O)--, C.sub.1-4-alkyl-NR.sup.N--C(.dbd.O)--, C.sub.1-4-alkyl-NR.sup.N--, C.sub.1-4-alkyl-C(.dbd.O)NR.sup.N--, C.sub.1-4-alkyl-S(.dbd.O).sub.2NR.sup.N--, --OH, C.sub.1-4-alkyl-O--,C.sub.1-4-alkyl-O--C.sub.1-4-alkyl-O--, C.sub.3-6-cycloalkyl-O--, heterocyclyl-O--, C.sub.1-4-alkyl-S(.dbd.O)--, C.sub.1-4-alkyl-S(.dbd.O).sub.2--, heterocyclyl, and heteroaryl, wherein any alkyl, cycloalkyl, and heterocyclyl group or sub-group withinthe groups mentioned is optionally substituted with 1 or more F atoms and optionally substituted with 1 or 2 groups independently selected from H.sub.3C--, H.sub.3C--O--, and --CN, wherein heterocyclyl is selected from a cyclobutyl group wherein 1CH.sub.2 group is replaced by --NR.sup.N-- or --O--; a saturated or partially unsaturated C.sub.5-6-cycloalkyl group wherein 1 CH.sub.2 group is replaced by --C(.dbd.O)--, --NR.sup.N--, --O--, --S(.dbd.O)-- or --S(.dbd.O).sub.2-- and/or 1 CH group isreplaced by N; a saturated or partially unsaturated C.sub.5-6-cycloalkyl group wherein 1 CH.sub.2 group is replaced by --NR.sup.N-- or --O--, a second CH.sub.2 group is replaced by --NR.sup.N--, --C(.dbd.O)--, --S(.dbd.O)-- or --S(.dbd.O).sub.2--,and/or 1 CH group is replaced by N; and a saturated or partially unsaturated C.sub.5-6-cycloalkyl group wherein 2 CH.sub.2 group are replaced by --NR.sup.N--, or a first CH.sub.2 group is replaced by --NR.sup.N--, a second CH.sub.2 group is replaced by--O--, and a third CH.sub.2 group is replaced by --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; and wherein heteroaryl is selected from a pyridin-2-onyl ring, a 5-membered heteroaromatic ring which contains 1or 2 heteroatoms independently selected from .dbd.N--, --NH--, --O--, and --S--, and a 6-membered heteroaromatic ring which contains 1 or 2=N-- atoms, and wherein in heteroaromatic rings with one or more NH groups each of them is replaced by NR.sup.N,and each heteroaryl group is optionally substituted with 1 or 2 substituents independently selected from F, Cl, --CH.sub.3, --CN, and --O--CH.sub.3; R.sup.6 is F, Cl, --CN, --CH.sub.3, --CF.sub.3, --OCH.sub.3, --OCF.sub.3, --S(.dbd.O)CH.sub.3, or--S(.dbd.O).sub.2--CH.sub.3; R.sup.N is H, H.sub.3C--, H.sub.3C--C(.dbd.O)--, or C.sub.1-3-alkyl-S(.dbd.O).sub.2--; and m is 1 or 2, or a salt thereof.

6. The compound according to claim 1, wherein: R.sup.1 is ##STR00455## R.sup.2 is F, Cl, or NC--; R.sup.3 is selected from the group consisting of C.sub.1-4-alkyl, C.sub.3-6-cycloalkyl-, C.sub.1-4-alkyl-O--, and C.sub.3-6-cycloalkyl-O--,wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is substituted with 1 group selected from R.sup.5 and optionally substituted with 1 or 2 H.sub.3C-- group; or selected fromH.sub.3C--C(.dbd.O)--, heterocyclyl-C(.dbd.O)--, H.sub.2N--C(.dbd.O)--, H.sub.3C--NR.sup.N--C(.dbd.O)--, heterocyclyl-O--, heteroaryl-O--, H.sub.2N--S(.dbd.O).sub.2--, heterocyclyl, phenyl, and heteroaryl, wherein each heterocyclyl group or sub-groupwithin the groups mentioned is optionally substituted with 1 or 2 groups independently selected from R.sup.5 and optionally substituted with 1 or more F atoms; each phenyl and heteroaryl group is optionally substituted with 1 or 2 substituentsindependently selected from R.sup.6; wherein heterocyclyl is selected from a cyclobutyl group wherein 1 CH.sub.2 group is replaced by --NH-- or --O--; a saturated or mono-unsaturated C.sub.5-6-cycloalkyl group wherein 1 CH.sub.2 group is replaced by--C(.dbd.O)--, --NH--, --O-- or --S(.dbd.O).sub.2-- and/or 1 CH group is replaced by N; a saturated or mono-unsaturated C.sub.5-6-cycloalkyl group wherein a first CH.sub.2 group is replaced by --NH-- or --O--, a second CH.sub.2 group is replaced by--NH--, --C(.dbd.O)-- or --S(.dbd.O).sub.2-- and/or 1 CH group is replaced by N; and wherein heteroaryl is selected from a 5-membered heteroaromatic ring which contains 1 or 2 heteroatoms independently of each other selected from .dbd.N--, --NH--,--O--, and --S--, and a 6-membered heteroaromatic ring which contains 1 or 2=N-- atoms, and wherein in heteroaryl and heterocyclyl rings with one or more NH group each of them is replaced with NR.sup.N or NR.sup.5; with the proviso that R.sup.3 in totalcannot be C.sub.1-4-alkyl-, C.sub.1-4-alkyl-O--C.sub.1-4-alkyl, HO--C.sub.1-4-alkyl, and C.sub.1-4-alkyl-O--; R.sup.5 is selected from the group consisting of C.sub.1-4-alkyl-, --CN, C.sub.3-6-cycloalkyl-, heterocyclyl-C(.dbd.O)--,H.sub.2N--C(.dbd.O)--, C.sub.1-4-alkyl-NR.sup.N--C(.dbd.O)--, C.sub.1-4-alkyl-NR.sup.N--, C.sub.1-4-alkyl-S(.dbd.O).sub.2NR.sup.N--, --OH, C.sub.1-4-alkyl-O--, C.sub.3-6-cycloalkyl-O--, heterocyclyl-O--, C.sub.1-4-alkyl-S(.dbd.O)--,C.sub.1-4-alkyl-S(.dbd.O).sub.2--, heterocyclyl, and heteroaryl, wherein any alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms and optionally substituted with 1 or 2 groupsindependently selected from H.sub.3C--, H.sub.3C--O--, and --CN, wherein heterocyclyl is selected from a cyclobutyl group wherein 1 CH.sub.2 group is replaced by --NR.sup.N-- or --O--; a saturated or partially unsaturated C.sub.5-6-cycloalkyl groupwherein 1 CH.sub.2 group is replaced by --C(.dbd.O)--, --NR.sup.N--, --O--, --S(.dbd.O)-- or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; a saturated or partially unsaturated C.sub.5-6-cycloalkyl group wherein a first CH.sub.2 group isreplaced by --NR.sup.N--, or --O--, a second CH.sub.2 group is replaced by --NR.sup.N--, --C(.dbd.O)--, --S(.dbd.O)--, or --S(.dbd.O).sub.2--, and/or 1 CH group is replaced by N; and a saturated or partially unsaturated C.sub.5-6-cycloalkyl groupwherein 2 CH.sub.2 groups are replaced by --NR.sup.N--, or a first CH.sub.2 group is replaced by --NR.sup.N--, a second CH.sub.2 group is replace by --O--, and a third CH.sub.2 group is replaced by --C(.dbd.O)--, --S(.dbd.O)-- or --S(.dbd.O).sub.2--and/or 1 CH group is replaced by N; and wherein heteroaryl is selected from a pyridin-2-onyl ring, a 5-membered heteroaromatic ring which contains 1 or 2 heteroatoms independently selected from .dbd.N--, --NH--, --O--, and --S--, and a 6-memberedheteroaromatic ring which contains 1 or 2=N-- atoms, and wherein in heteroaromatic rings with one or more NH group each of them is replaced by NR.sup.N, and each heteroaryl group is optionally substituted with 1 or 2 substituents independently selectedfrom F, Cl, --CH.sub.3, --CN, and --O--CH.sub.3; R.sup.6 is F, CH.sub.3, CN, or --OCH.sub.3; R.sup.N is H, H.sub.3C--, H.sub.3C--C(.dbd.O)--, or C.sub.1-3-alkyl-S(.dbd.O).sub.2--; and m is 1 or 2, or a salt thereof.

7. A pharmaceutically acceptable salt of a compound according to claim 1.

8. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salts thereof and an inert carrier or diluent.

9. A method for palliatively treating diseases or conditions which are influenced by the modulation of the function of GPR40 in a patient in need thereof, comprising administering a compound according to claim 1 or a pharmaceutically acceptablesalt thereof to the patient.

10. The method according to claim 9, wherein the diseases or conditions which are influenced by the modulation of the function of GPR40 in a patient are selected from diabetes, insulin resistance, obesity, cardiovascular disease, anddyslipidemia.

11. The pharmaceutical composition according to claim 8, further comprising an additional therapeutic agent.

12. The pharmaceutical composition according to claim 11, wherein the additional therapeutic agent is an antidiabetic agent, agents for the treatment of overweight and/or obesity, or an agents for the treatment of high blood pressure, heartfailure, and/or atherosclerosis.

13. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-4-(2,6-dimethyl-4-((3-methyloxetan-3-yl)methoxy)phenyl)-7-f- luoro-2,3-dihydro-1H-inden-1 -yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

14. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-7-fluoro-4-(4-(3-hydroxy-3-methylbutoxy)-2,6-dimethylphenyl- )-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

15. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-4-(2,6-dimethyl-4-(tetrahydro-2H-pyran-4-yloxy)phenyl)-7-fl- uoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

16. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-4-(2,6-dimethyl-4-((S)-tetrahydrofuran-3-yloxy)phenyl)-7-fl- uoro-2,3-dihydro-1H-inden-1-yloxy)-2,3 -dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

17. The compound according to claim 1, wherein the compound is 2((S)-6-((R)-4-(2,6-dimethyl-4-((R)-tetrahydrofuran-3-yloxy)phenyl)-7-flu- oro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

18. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-7-fluoro-4-(4-(2-hydroxy-2-methylpropoxy)-2,6-dimethylpheny- l)-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

19. The compound according to claim 1, wherein the compound is 2-((S)-6-(R)-7-fluoro-4-(4-(3 -hydroxy-2,2-dimethylpropoxy)-2,6-dimethylphenyl)-2,3-dihydro-1H-inden-1-- yloxy)-2,3 -dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

20. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-4-(2,6-dimethyl-4-((1,1-dioxotetrahydro-2H-thiopyran-4-yl)m- ethoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofura- n-3-yl)acetic acid or a saltthereof.

21. The compound according to claim 1, wherein the compound is ((S)-6-{(R)-7-fluoro-4-[4-(2-methanesulfonyl-2-methylpropoxy)-2,6-dimethy- lphenyl]indan-1-yloxy}-2,3 -dihydro-benzofuran-3-yl)acetic acid or a salt thereof.

22. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-4-(4-(2-cyano-2-methylpropoxy)-2,6-dimethylphenyl)-7-fluoro- -2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

23. The compound according to claim 1, wherein the compound is 2-((S)-6((R)-7-fluoro-4-(4-((4-hydroxytetrahydro-2H-pyran-4-yl)methoxy)-2- ,6-dimethylphenyl)-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-y- l)acetic acid or a saltthereof.

24. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-7-fluoro-4-(4-((1,1-dioxo-4-hydroxytetrahydro-2H-thiopyran-- 4-yl)methoxy)-2,6-dimethylphenyl)-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydr- obenzofuran-3-yl)acetic acidor a salt thereof.

25. The compound according to claim 1, wherein the compound is 2((S)-6((R)-4-(2,6-dimethyl-4-(2-methyl-2H-tetrazol-5-yl)phenyl)-7-fluoro- -2,3-dihydro-1H-inden-1-yloxy)-2,3 -dihydrobenzofuran-3-yl)acetic acid or a salt thereof.

26. The compound according to claim 1, wherein the compound is 2-((S)-6-((R)-7-fluoro-4-(4-(2-(2-hydroxy-2-methylpropyl)-2H-tetrazol-5-y- l)-2,6-dimethylphenyl)-2,3 -dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a saltthereof.

27. The compound according to claim 1, wherein the compound is {(S)-6-[(R)-4-(2,6-dimethyl-4-(5-methylpyrimidin-2-yl)phenyl)-7-fluoroind- an-l-yloxyl -2,3-dihydrobenzofuran-3-yl}acetic acid or a salt thereof.

28. The compound according to claim 1, wherein the compound is {(S)-6[(R)-4-(2,6-dimethyl-4-(6-methylpyridazin-3-yl)phenyl)-7-fluoroinda- n-1-yloxy]-2,3-dihydrobenzofuran-3-yl}acetic acid or a salt thereof.

29. The compound according to claim 1, wherein the compound is {(S)-6[(R)-4-(2,6-dimethyl-4-(1-methylimidazol-4-yl)phenyl)-7-fluoroindan- -1-yloxyl-2,3-dihydrobenzofuran-3-yl}-acetic acid or a salt thereof.

30. The compound according to claim 1, wherein the compound is {(S)-6[(R)-4-(2,6-dimethyl-4-(6-methylpyridin-2-yl)phenyl)-7-fluoroindan-- 1-yloxyl-2,3-dihydrobenzofuran-3-yl}-acetic acid or a salt thereof.

31. The compound according to claim 1, wherein the compound is {(S)-6-[(R)-4-(2,6)-dimethyl-4-(4-methylpyridin-2-yl)-7-flouroindan-1-ylo- xy]-2,3-dihydrobenzofuran-3-yl }-acetic acid or a salt thereof.

32. The compound according to claim 1, wherein the compound is 2((S)-6-((R)-4-(2,6-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)phenyl)- -7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid or a salt thereof.
Description:
 
 
  Recently Added Patents
Baseball themed hand clap maraca
Transmitter and receiver for streaming media including packet padding
Method of treating a preceramic material
Device and method including a soldering process
System and method for hybrid risk modeling of turbomachinery
Pointing device, display apparatus and pointing system, and location data generation method and display method using the same
Method of driving stereoscopic display apparatus and stereoscopic display apparatus
  Randomly Featured Patents
Polyolefin with improved processing properties
Throttle holding device for better heater performance
Individual hydraulic circuit modules for engine with hydraulically-controlled cylinder deactivation
Tailwind alerting system to prevent runway overruns
Radio frequency interference suppressing ignition distributor rotor
Zoom lens system and image-taking apparatus having the same
Multi-frame groove-mount wall system
Image pickup lens, camera module using the same, image pickup lens manufacturing method and camera module manufacturing method
Enclosure for an air aspirating machine
System and method of maintaining data integrity in a flash storage device